scispace - formally typeset
Search or ask a question
Institution

Erasmus University Rotterdam

EducationRotterdam, Zuid-Holland, Netherlands
About: Erasmus University Rotterdam is a education organization based out in Rotterdam, Zuid-Holland, Netherlands. It is known for research contribution in the topics: Population & Health care. The organization has 35466 authors who have published 91288 publications receiving 4510972 citations. The organization is also known as: EUR.


Papers
More filters
Journal ArticleDOI
Roby Joehanes, Allan C. Just1, Riccardo E. Marioni2, Luke C. Pilling1, Lindsay M. Reynolds1, Pooja R. Mandaviya3, Weihua Guan, Tao Xu2, Cathy E. Elks2, Stella Aslibekyan1, Hortensia Moreno-Macías4, Jennifer A. Smith3, Jennifer A. Brody3, Radhika Dhingra3, Paul Yousefi5, James S. Pankow, Sonja Kunze, Sonia Shah6, Allan F. McRae6, Kurt Lohman6, Jin Sha7, Jin Sha8, Devin Absher7, Luigi Ferrucci7, Wei Zhao9, Ellen W. Demerath8, Jan Bressler6, Megan L. Grove7, Tianxiao Huan9, Tianxiao Huan10, Chunyu Liu5, Chunyu Liu3, Chunyu Liu2, Michael M. Mendelson, Chen Yao1, Douglas P. Kiel4, Annette Peters11, Rui Wang-Sattler, Peter M. Visscher12, Naomi R. Wray, John M. Starr13, Jingzhong Ding3, Carlos J. Rodriguez1, Nicholas J. Wareham, Marguerite R. Irvin2, Degui Zhi2, Myrto Barrdahl2, Paolo Vineis1, Srikant Ambatipudi, André G. Uitterlinden2, Albert Hofman14, Joel Schwartz10, Elena Colicino15, Lifang Hou3, Pantel S. Vokonas2, D. Hernandez16, Andrew B. Singleton, Stefania Bandinelli17, Stephen Turner, Erin B. Ware, Alicia K. Smith, Torsten Klengel18, Elisabeth B. Binder19, Bruce M. Psaty20, Kent D. Taylor, Sina A. Gharib1, Brenton R. Swenson21, Liming Liang22, Dawn L. DeMeo, George T. O'Connor, Zdenko Herceg1, Kerry J. Ressler23, Karen N. Conneely11, N. Sotoodehnia24, Sharon L.R. Kardia2, David Melzer17, Andrea A. Baccarelli1, Joyce B. J. van Meurs1, Isabelle Romieu3, Donna K. Arnett, Ken K. Ong, Yongmei Liu19, M. Waldenberger25, Ian J. Deary1, Myriam Fornage26, Daniel Levy, Stephanie J. London11 
TL;DR: Cigarette smoking has a broad impact on genome-wide methylation that, at many loci, persists many years aftersmoking cessation, indicating a pattern of persistent altered methylation, with attenuation, after smoking cessation.
Abstract: Background —DNA methylation leaves a long-term signature of smoking exposure and is one potential mechanism by which tobacco exposure predisposes to adverse health outcomes, such as cancers, osteoporosis, lung, and cardiovascular disorders. Methods and Results —To comprehensively determine the association between cigarette smoking and DNA methylation, we conducted a meta-analysis of genome-wide DNA methylation assessed using the Illumina BeadChip 450K array on 15,907 blood derived DNA samples from participants in 16 cohorts (including 2,433 current, 6,518 former, and 6,956 never smokers). Comparing current versus never smokers, 2,623 CpG sites (CpGs), annotated to 1,405 genes, were statistically significantly differentially methylated at Bonferroni threshold of p<1×10-7 (18,760 CpGs at False Discovery Rate (FDR)<0.05). Genes annotated to these CpGs were enriched for associations with several smoking-related traits in genome-wide studies including pulmonary function, cancers, inflammatory diseases and heart disease. Comparing former versus never smokers, 185 of the CpGs that differed between current and never smokers were significant p<1×10-7 (2,623 CpGs at FDR<0.05), indicating a pattern of persistent altered methylation, with attenuation, after smoking cessation. Transcriptomic integration identified effects on gene expression at many differentially methylated CpGs. Conclusions —Cigarette smoking has a broad impact on genome-wide methylation that, at many loci, persists many years after smoking cessation. Many of the differentially methylated genes were novel genes with respect to biologic effects of smoking, and might represent therapeutic targets for prevention or treatment of tobacco-related diseases. Methylation at these sites could also serve as sensitive and stable biomarkers of lifetime exposure to tobacco smoke.

628 citations

Journal ArticleDOI
26 Jun 2008-BMJ
TL;DR: The evidence underlying quality improvement collaboratives is positive but limited and the effects cannot be predicted with great certainty, so further knowledge of the basic components effectiveness, cost effectiveness, and success factors is crucial to determine the value of quality improvement Collaboratives.
Abstract: Objective To evaluate the effectiveness of quality improvement collaboratives in improving the quality of care. Data sources Relevant studies through Medline, Embase, PsycINFO, CINAHL, and Cochrane databases. Study selection Two reviewers independently extracted data on topics, participants, setting, study design, and outcomes. Data synthesis Of 1104 articles identified, 72 were included in the study. Twelve reports representing nine studies (including two randomised controlled trials) used a controlled design to measure the effects of the quality improvement collaborative intervention on care processes or outcomes of care. Systematic review of these nine studies showed moderate positive results. Seven studies (including one randomised controlled trial) reported an effect on some of the selected outcome measures. Two studies (including one randomised controlled trial) did not show any significant effect. Conclusions The evidence underlying quality improvement collaboratives is positive but limited and the effects cannot be predicted with great certainty. Considering that quality improvement collaboratives seem to play a key part in current strategies focused on accelerating improvement, but may have only modest effects on outcomes at best, further knowledge of the basic components effectiveness, cost effectiveness, and success factors is crucial to determine the value of quality improvement collaboratives.

627 citations

Journal ArticleDOI
TL;DR: Four compounds are identified inhibiting MERS-CoV replication in the low-micromolar range (50% effective concentrations [EC50s], 3 to 8 μM) and may offer a starting point for treatment of patients infected with zoonotic coronavirus infections.
Abstract: Coronaviruses can cause respiratory and enteric disease in a wide variety of human and animal hosts. The 2003 outbreak of severe acute respiratory syndrome (SARS) first demonstrated the potentially lethal consequences of zoonotic coronavirus infections in humans. In 2012, a similar previously unknown coronavirus emerged, Middle East respiratory syndrome coronavirus (MERS-CoV), thus far causing over 650 laboratory-confirmed infections, with an unexplained steep rise in the number of cases being recorded over recent months. The human MERS fatality rate of ∼ 30% is alarmingly high, even though many deaths were associated with underlying medical conditions. Registered therapeutics for the treatment of coronavirus infections are not available. Moreover, the pace of drug development and registration for human use is generally incompatible with strategies to combat emerging infectious diseases. Therefore, we have screened a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. If such compounds proved sufficiently potent, their efficacy might be directly assessed in MERS patients. We identified four compounds (chloroquine, chlorpromazine, loperamide, and lopinavir) inhibiting MERS-CoV replication in the low-micromolar range (50% effective concentrations [EC(50)s], 3 to 8 μM). Moreover, these compounds also inhibit the replication of SARS coronavirus and human coronavirus 229E. Although their protective activity (alone or in combination) remains to be assessed in animal models, our findings may offer a starting point for treatment of patients infected with zoonotic coronaviruses like MERS-CoV. Although they may not necessarily reduce viral replication to very low levels, a moderate viral load reduction may create a window during which to mount a protective immune response.

626 citations

Journal ArticleDOI
TL;DR: At five years there was no difference in mortality between stenting and surgery for multivessel disease, and overall MACCE was higher in the stent group, driven by the increased need for repeat revascularization.

624 citations

Journal ArticleDOI
TL;DR: In spite of its dependence upon operator's training, stress echocardiography is today the best (most cost-effective and risk-effective) possible imaging choice to achieve the still elusive target of sustainable cardiac imaging in the field of noninvasive diagnosis of coronary artery disease.
Abstract: Stress echocardiography is the combination of 2D echocardiography with a physical, pharmacological or electrical stress. The diagnostic end point for the detection of myocardial ischemia is the induction of a transient worsening in regional function during stress. Stress echocardiography provides similar diagnostic and prognostic accuracy as radionuclide stress perfusion imaging, but at a substantially lower cost, without environmental impact, and with no biohazards for the patient and the physician. Among different stresses of comparable diagnostic and prognostic accuracy, semisupine exercise is the most used, dobutamine the best test for viability, and dipyridamole the safest and simplest pharmacological stress and the most suitable for combined wall motion coronary flow reserve assessment. The additional clinical benefit of myocardial perfusion contrast echocardiography and myocardial velocity imaging has been inconsistent to date, whereas the potential of adding – coronary flow reserve evaluation of left anterior descending coronary artery by transthoracic Doppler echocardiography adds another potentially important dimension to stress echocardiography. New emerging fields of application taking advantage from the versatility of the technique are Doppler stress echo in valvular heart disease and in dilated cardiomyopathy. In spite of its dependence upon operator’s training, stress echocardiography is today the best (most cost-effective and risk-effective) possible imaging choice to achieve the still elusive target of sustainable cardiac imaging in the field of noninvasive diagnosis of coronary artery disease.

624 citations


Authors

Showing all 35695 results

NameH-indexPapersCitations
Walter C. Willett3342399413322
Meir J. Stampfer2771414283776
Albert Hofman2672530321405
Graham A. Colditz2611542256034
Paul M. Ridker2331242245097
Ralph B. D'Agostino2261287229636
John Q. Trojanowski2261467213948
David J. Hunter2131836207050
André G. Uitterlinden1991229156747
Robert M. Califf1961561167961
Eric J. Topol1931373151025
Frank E. Speizer193636135891
Bernard Rosner1901162147661
William B. Kannel188533175659
Patrick W. Serruys1862427173210
Network Information
Related Institutions (5)
Emory University
122.4K papers, 6M citations

94% related

University of Pittsburgh
201K papers, 9.6M citations

94% related

University of Pennsylvania
257.6K papers, 14.1M citations

93% related

Duke University
200.3K papers, 10.7M citations

93% related

Utrecht University
139.3K papers, 6.2M citations

92% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202397
2022317
20216,115
20205,342
20194,754
20184,357